Menu
Back to User profile » Dr Yu Feng
Papers published by Dr Yu Feng:
Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Han C, Wang G, Chan S, Kato T, Ng CH, Tan W, Zhang L, Feng Y, Liu CY
Neuropsychiatric Disease and Treatment 2020, 16:2929-2941
Published Date: 3 December 2020
Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, Zhang L, Feng Y, Ng CH
Neuropsychiatric Disease and Treatment 2020, 16:2943-2959
Published Date: 3 December 2020
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L
Neuropsychiatric Disease and Treatment 2019, 15:1685-1694
Published Date: 27 June 2019
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Neuropsychiatric Disease and Treatment 2018, 14:1107-1117
Published Date: 26 April 2018
Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
Li N, Feng Y, Lu HF, Cai SL, Zhuo JM, Si TM, Zhang LL
Neuropsychiatric Disease and Treatment 2018, 14:825-837
Published Date: 22 March 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Neuropsychiatric Disease and Treatment 2017, 13:2045-2056
Published Date: 2 August 2017
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
Si TM, Zhang KR, Tang JS, Fang MS, Li KQ, Zhuo JM, Feng Y
Neuropsychiatric Disease and Treatment 2015, 11:1483-1492
Published Date: 22 June 2015